Physician profile
Brian L Smith
NPI 1619926250
$8,577.68
in general payments reported to CMS, 2019-2025
49 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $531 · 2021: $943 · 2022: $1,256 · 2023: $1,024 · 2024: $1,383 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,491 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,490.76 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,180.78 | 2021-2025 | Vraylar, Qulipta, Viberzi |
| Astrazeneca Pharmaceuticals LP | $948.63 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $784.28 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $674.49 | 2019-2025 | |
| Novo Nordisk INC | $585.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $406.38 | 2019-2025 | Uplizna, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.63 | 2019-2025 | Jardiance |
| Abbott Laboratories | $345.03 | 2021-2025 | Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $295.89 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $294.85 | 2019-2025 | Xarelto, Spravato |
| Allergan, INC. | $257.94 | 2019-2020 | |
| Glaxosmithkline, LLC. | $229.07 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $210.90 | 2019-2024 | Belsomra, Vaxneuvance, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.31 | 2019-2023 | Xifaxan |
| Exact Sciences Corporation | $144.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.